Soldati Federico, Lambercy Karma, Simon Christian
Department of Otolaryngology-Head and Neck Surgery CHUV, University of Lausanne Lausanne Switzerland.
Laryngoscope Investig Otolaryngol. 2022 May 5;7(3):746-750. doi: 10.1002/lio2.795. eCollection 2022 Jun.
Recovery of swallowing in patients treated with trans-oral robotic surgery (TORS) is in general considered as favorable. However, patients afflicted with a secondary primary carcinoma of the head and neck may be more vulnerable to swallowing dysfunctions after trans-oral surgery as a consequence of previous treatments.
This is a retrospective monocentric study on patients undergoing TORS for second primary squamous cell carcinoma between 2013 and 2017 (follow-up until June 2021). Swallowing performance was assessed via the functional outcome swallowing scale (FOSS). Also, overall survival (OS), disease-free survival (DS) and disease-specific survival (DSS) were evaluated.
Eighteen patients (median 62 years) underwent TORS with curative intent for T1-2 oropharyngeal and supraglottic secondary primaries. The average follow-up was of 52 months. All cases were resected R0 using TORS. 84% of patients had a post-treatment FOSS score equal or better upon last follow-up compared with pre-treatment. Only one patient required a percutaneous gastrostomy long term. DSS/DFS/OS at 5 years was 94%, 60%, and 67%, respectively. The main cause of death was metachronous pulmonary neoplasia.
Our study demonstrates encouraging results in terms of swallowing recovery in patients undergoing TORS for selected secondary primaries of the oropharynx and supraglottic larynx. Further studies into trans-oral surgery for this condition seem therefore warranted. Case series; Level 4.
经口机器人手术(TORS)治疗的患者吞咽功能恢复情况总体被认为良好。然而,患有头颈部继发性原发性癌的患者由于先前的治疗,经口手术后可能更容易出现吞咽功能障碍。
这是一项回顾性单中心研究,研究对象为2013年至2017年间接受TORS治疗的继发性原发性鳞状细胞癌患者(随访至2021年6月)。通过功能性吞咽结果量表(FOSS)评估吞咽功能。此外,还评估了总生存期(OS)、无病生存期(DS)和疾病特异性生存期(DSS)。
18例患者(中位年龄62岁)接受了TORS治疗,目的是治愈T1-2期口咽和会厌上继发性原发性癌。平均随访时间为52个月。所有病例均通过TORS实现R0切除。与治疗前相比,84%的患者在最后一次随访时治疗后的FOSS评分相同或更高。只有一名患者长期需要经皮胃造瘘术。5年时的DSS/DFS/OS分别为94%、60%和67%。主要死亡原因是异时性肺肿瘤。
我们的研究表明,对于接受TORS治疗的口咽和会厌上喉特定继发性原发性癌患者,吞咽恢复方面的结果令人鼓舞。因此,有必要对这种情况的经口手术进行进一步研究。病例系列;4级。